220 related articles for article (PubMed ID: 10452972)
1. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
[TBL] [Abstract][Full Text] [Related]
2. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
3. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
5. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R; Germanov E; Shimaoka T; Johnston B
J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
[TBL] [Abstract][Full Text] [Related]
7. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
8. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.
Carnaud C; Lee D; Donnars O; Park SH; Beavis A; Koezuka Y; Bendelac A
J Immunol; 1999 Nov; 163(9):4647-50. PubMed ID: 10528160
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
13. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
Seino K; Motohashi S; Fujisawa T; Nakayama T; Taniguchi M
Cancer Sci; 2006 Sep; 97(9):807-12. PubMed ID: 16805854
[TBL] [Abstract][Full Text] [Related]
14. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.
Nagaraj S; Ziske C; Strehl J; Messmer D; Sauerbruch T; Schmidt-Wolf IG
Int Immunol; 2006 Aug; 18(8):1279-83. PubMed ID: 16772371
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
Nicol AJ; Tazbirkova A; Nieda M
Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
[TBL] [Abstract][Full Text] [Related]
17. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
18. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
19. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
20. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance.
Ito H; Ando K; Ishikawa T; Nakayama T; Taniguchi M; Saito K; Imawari M; Moriwaki H; Yokochi T; Kakumu S; Seishima M
Int Immunol; 2008 Jul; 20(7):869-79. PubMed ID: 18487227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
